CCO Oncology Podcast
Ein Podcast von Clinical Care Options
189 Folgen
-
Treatment Options for Patients With Multiple Myeloma After First Relapse
Vom: 14.7.2021 -
Precision Medicine in Gynecologic Cancers: Expert Answers to Your Questions
Vom: 12.7.2021 -
Expert Answers to Questions on Managing Neurofibromatosis Type 1 and MEK Inhibitors for NF1-Associated Plexiform Neurofibromas
Vom: 12.7.2021 -
Expert Answers to Questions on PARP Inhibitor Combinations in Prostate Cancer
Vom: 30.6.2021 -
Immunotherapy for Advanced HCC: Current Options and Expert Answers to Clinician Questions
Vom: 29.6.2021 -
Expert Insight on Key Data From ASCO 2021 Informing Treatment for Endometrial, Ovarian, and Cervical Cancer
Vom: 24.6.2021 -
Optimizing Therapy for Relapsed/Refractory Multiple Myeloma: Expert Answers to Your Questions
Vom: 17.6.2021 -
Experts Answer FAQs on Biomarker-Driven Therapy for Non-Small-Cell Lung Cancer
Vom: 19.5.2021 -
Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC
Vom: 18.5.2021 -
Immunotherapy for Advanced HCC: Case Series
Vom: 17.5.2021 -
Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Germany
Vom: 13.5.2021 -
Managing Toxicities Associated With FGFR Inhibitors in Urothelial Cancer and Beyond
Vom: 4.5.2021 -
Optimizing the Timing and Sequencing of Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer
Vom: 28.4.2021 -
Expert Answers to Questions on Contemporary Management of Multiple Myeloma
Vom: 22.4.2021 -
Combining PARP inhibitors With Other Treatments for Men With Prostate Cancer: Clinical Trial Updates
Vom: 19.4.2021 -
Rationale for Combining PARP Inhibitors With Other Therapies in Prostate Cancer
Vom: 15.4.2021 -
Expert Insight on Key Data From SGO 2021 Informing Treatment for Endometrial and Ovarian Cancer
Vom: 6.4.2021 -
Expert Answers to Questions on PARP Inhibition for Prostate Cancer
Vom: 6.4.2021 -
Expert Insights on Highlights From ASH 2020 on Lymphomas/CLL
Vom: 26.3.2021 -
Improving Outcomes in EGFR-Mutated Non-Small-Cell Lung Cancer: Global Insights on Evolving Practice Standards
Vom: 25.3.2021
Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
